Søren Bregenholt
Chief Executive Officer bij ALLIGATOR BIOSCIENCE AB
Profiel
Søren Bregenholt is currently the Chief Executive Officer at Alligator Bioscience AB.
He is also the Chairman at Medicon Valley Alliance FMBA, A Bioscience Incentive AB, and Atlas Therapeutics AB.
Additionally, he serves as a Director at Oblique Therapeutics AB.
Previously, he held the position of Chief Executive Officer & Director at Macrophage Pharma Ltd.
He also worked as an Investment Manager at Novo Nordisk A and as the Chief Operating Officer at Symphogen A.
Dr. Bregenholt obtained a doctorate degree from the University of Copenhagen.
Actieve functies van Søren Bregenholt
Bedrijven | Functie | Begin |
---|---|---|
ALLIGATOR BIOSCIENCE AB | Chief Executive Officer | 01-06-2021 |
Medicon Valley Alliance FMBA
Medicon Valley Alliance FMBA Miscellaneous Commercial ServicesCommercial Services Medicon Valley Alliance FMBA operates a life science cluster that spans across Denmark and Sweden. The non-profit company is based in the Medicon Valley region. | Chairman | - |
A Bioscience Incentive AB | Chairman | - |
Atlas Therapeutics AB
Atlas Therapeutics AB Pharmaceuticals: MajorHealth Technology Part of Alligator Bioscience AB, Atlas Therapeutics AB develops and manufactures antibody drugs. The private company is based in Stockholm, Sweden. Atlas Therapeutics was acquired by Alligator Bioscience AB on October 18, 2013. | Chairman | - |
Oblique Therapeutics AB
Oblique Therapeutics AB Pharmaceuticals: MajorHealth Technology Oblique Therapeutics AB is a privately held Swedish biotech company that develops innovative new medicines for severe diseases with a large unmet medical need, focusing on pain and advanced cancer. The company is based in Gothenburg, Sweden. The company uses abiprot®, an in-house-invented, next-generation antibody platform that can generate antibodies with programmed function against the full human proteome. The portfolio comprises several antibody candidates and the small molecule ot-1096 in triple-negative breast cancer. In addition, two antibody programs are run in R&D collaborations with pharma companies. The company was founded in 2015 by Jan Owe Owesson Orwar, and Christer Nordstedt has been the CEO of the company since 2022. | Director/Board Member | - |
Eerdere bekende functies van Søren Bregenholt
Bedrijven | Functie | Einde |
---|---|---|
NOVO NORDISK A/S | Chief Investment Officer | - |
Macrophage Pharma Ltd.
Macrophage Pharma Ltd. BiotechnologyHealth Technology Macrophage Pharma Ltd. engages in research and experimental development on biotechnology. The company is headquartered in Berkhamsted, the United Kingdom. | Chief Executive Officer | - |
Symphogen A/S
Symphogen A/S Pharmaceuticals: MajorHealth Technology Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark. | Chief Operating Officer | - |
Opleiding van Søren Bregenholt
University of Copenhagen | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 2 |
---|---|
NOVO NORDISK A/S | Health Technology |
ALLIGATOR BIOSCIENCE AB | Health Technology |
Bedrijven in privébezit | 6 |
---|---|
Symphogen A/S
Symphogen A/S Pharmaceuticals: MajorHealth Technology Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark. | Health Technology |
Medicon Valley Alliance FMBA
Medicon Valley Alliance FMBA Miscellaneous Commercial ServicesCommercial Services Medicon Valley Alliance FMBA operates a life science cluster that spans across Denmark and Sweden. The non-profit company is based in the Medicon Valley region. | Commercial Services |
Atlas Therapeutics AB
Atlas Therapeutics AB Pharmaceuticals: MajorHealth Technology Part of Alligator Bioscience AB, Atlas Therapeutics AB develops and manufactures antibody drugs. The private company is based in Stockholm, Sweden. Atlas Therapeutics was acquired by Alligator Bioscience AB on October 18, 2013. | Health Technology |
A Bioscience Incentive AB | |
Macrophage Pharma Ltd.
Macrophage Pharma Ltd. BiotechnologyHealth Technology Macrophage Pharma Ltd. engages in research and experimental development on biotechnology. The company is headquartered in Berkhamsted, the United Kingdom. | Health Technology |
Oblique Therapeutics AB
Oblique Therapeutics AB Pharmaceuticals: MajorHealth Technology Oblique Therapeutics AB is a privately held Swedish biotech company that develops innovative new medicines for severe diseases with a large unmet medical need, focusing on pain and advanced cancer. The company is based in Gothenburg, Sweden. The company uses abiprot®, an in-house-invented, next-generation antibody platform that can generate antibodies with programmed function against the full human proteome. The portfolio comprises several antibody candidates and the small molecule ot-1096 in triple-negative breast cancer. In addition, two antibody programs are run in R&D collaborations with pharma companies. The company was founded in 2015 by Jan Owe Owesson Orwar, and Christer Nordstedt has been the CEO of the company since 2022. | Health Technology |